Parastoo Bahrami Dahi MD

PubMed

• Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
  Jae H Park, M Lia Palomba, Karlo Perica, Sean M Devlin, Gunjan Shah
  Journal of Clinical Oncology. 2025-07-20
• Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.
  Mohamed L Sorror, Wael Saber, Brent Logan, Nancy Geller, Anna Bellach
  Blood Advances. 2025-07-08
• Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.
  Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian
  Blood Cancer Journal. 2025-07-02

Journal Articles

• Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma  
  Parastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature
• End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center  
  Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018